COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #224 of 264
12/23 Late treatment study
Taccone et al., The Lancet Regional Health - Europe, doi:10.1016/j.lanepe.2020.100019 (Peer Reviewed)
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium
Source   PDF   Share   Tweet
Retrospective 1,747 ICU patients in Belgium showing lower mortality with HCQ, multivariate mixed effects analysis HCQ aOR 0.64 [0.45-0.92].

Taccone et al., 12/23/2020, retrospective, Belgium, Europe, peer-reviewed, 10 authors.
risk of death, 24.7% lower, RR 0.75, p < 0.001, treatment 449 of 1308 (34.3%), control 183 of 439 (41.7%), odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.